Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

John Millichap

Neurology with Special Qualifications in Child Neurology Chicago, IL Medical Doctor

NPI 1225211600 CMS profile 1251896

1 E Erie St Ste 525-4066, Chicago, IL 60611

Open in the dashboard

General payments

$84,318

87 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$28,833 paid to institutions, not to them · program years 2019–2021

Through program year 2024, John Millichap of Chicago, IL is reported in the CMS Open Payments database as having received $84,318 across 87 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $28,833 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 95th percentile of Neurology with Special Qualifications in Child Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $24 1
2023 General $59 1
2022 General $12,441 13
2021 General $14,409 16
2020 General $27,757 24
2019 General $29,629 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Millichap
  • Neurology with Special Qualifications in Child Neurology median
  • Middle half of Neurology with Special Qualifications in Child Neurology
  • National median

In program year 2025, general payments to John Millichap were reported at $0. Among 1,228 Neurology with Special Qualifications in Child Neurology profiles paid that year, the median was $276 and the middle half received between $87 and $1,522.

Show as a table
Year John Millichap Neurology with Special Qualifications in Child Neurology median Middle half National median
2019 $29,629 $262 $68–$1,313 $163
2020 $27,757 $188 $46–$1,222 $114
2021 $14,409 $183 $45–$1,356 $132
2022 $12,441 $229 $72–$1,177 $149
2023 $59 $269 $93–$1,195 $160
2024 $24 $300 $98–$1,428 $164
2025 $0 $276 $87–$1,522 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Greenwich Biosciences, Inc. $17,328 26 payments
  2. Mallinckrodt Hospital Products Inc. $12,245 4 payments
  3. Mallinckrodt Enterprises LLC $11,671 6 payments
  4. Neurelis, Inc. $11,538 9 payments
  5. Eisai Inc. $8,893 11 payments
  6. Sunovion Pharmaceuticals Inc. $5,265 7 payments
  7. BioMarin Pharmaceutical Inc. $3,362 6 payments
  8. ACADIA Pharmaceuticals Inc $3,150 2 payments
  9. UCB, Inc. $2,477 4 payments
  10. Eisai Co., Ltd. $2,400 1 payment
  11. Other $5,990 11 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $49,003 28 payments
  2. Consulting Fee $26,624 15 payments
  3. Travel and Lodging $6,473 17 payments
  4. Food and Beverage $1,756 25 payments
  5. Education $462 2 payments
Products named General payments · program years 2019–2024
  1. Epidiolex $17,328 26 payments
  2. ACTHAR Immunology $12,245 4 payments
  3. ACTHAR Autoimmune And Rare Disease $11,671 6 payments
  4. VALTOCO $11,538 9 payments
  5. Banzel $7,213 10 payments
  6. APTIOM $5,265 7 payments
  7. Fycompa $4,080 2 payments
  8. Brineura $3,362 6 payments
  9. Briviact $2,298 2 payments
  10. VNS THERAPY SENTIVA MODEL 1000 GENERATOR $1,725 2 payments
  11. Other $2,425 7 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$67,829

Medicare's payments for the services billed

Medicare patients

445

Average age 73

Services billed

628

232 women, 213 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Diabetes 46%
Chronic kidney disease 46%
Depression 45%
Heart failure 41%
Ischemic heart disease 40%
Alzheimer's or dementia 35%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

87 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology with Special Qualifications in Child Neurology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record